# Agnostic Therapy in Rare Solid Tumors

> **NCT06638931** · PHASE2 · RECRUITING · sponsor: **Instituto do Cancer do Estado de São Paulo** · enrollment: 28 (estimated)

## Conditions studied

- Urachal Cancer
- Parathyroid Carcinoma
- Fibrolamellar Carcinoma
- Angiosarcoma
- Secretory Carcinoma of Breast
- Anal Neoplasms
- Metaplastic Breast Carcinoma
- Translocation Renal Cell Carcinoma
- Carcinosarcoma
- Small Intestine Neoplasms
- Cholangiocarcinoma
- Sertoli-Leydig Cell Tumor
- Adenoid Cystic Carcinoma
- Mesothelioma
- Neuroblastoma
- Adrenal Gland Neoplasms
- Penile Neoplasms
- Apocrine Carcinoma
- Fibrosarcoma
- Cancer of Unknown Primary
- Hemangioblastoma
- Thyroid Neoplasms
- Hepatoblastoma
- Fallopian Tube Neoplasms
- Leiomyosarcoma
- Vaginal Neoplasms
- Neurofibrosarcoma
- Gallbladder Neoplasms
- Osteosarcoma
- Biliary Tract Neoplasms
- Clear Cell Endometrial Cancer
- Yolk Sac Tumor
- Vulvar Neoplasms
- Kaposi Sarcoma
- Ovarian Epithelial Cancer
- Soft Tissue Sarcoma
- Urethral Neoplasms
- Granulosa Cell Tumor
- Primitive Neuroectodermal Tumor
- Neuroendocrine Tumors
- Trophoblastic Tumor

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06638931
- **Lead sponsor:** Instituto do Cancer do Estado de São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-16
- **Primary completion:** 2026-07
- **Final completion:** 2028-05
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06638931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06638931, "Agnostic Therapy in Rare Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06638931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*